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Abstract: Hypothalamic hamartoma (HH) is a rare, congenital, and benign lesion of the tuber
cinereum, typically presenting with central precocious puberty (CPP), gelastic seizure, and devel-
opmental delay. This study aimed to investigate CPP in HH patients and compare clinical features
between before and after gonadotropin-releasing hormone (GnRH) agonist treatment. A total of
30 HH patients under 18 years of age who visited Severance Children’s Hospital between January
2005 and May 2020 were retrospectively reviewed. Fourteen patients were male (46.7%) and sixteen
(53.3%) were female, with a mean age at diagnosis was4.2 ± 2.9 years. During follow-up, 24 patients
(80.0%) were diagnosed with CPP, 15 patients (50.0%) had gelastic seizure, and 13 patients (43.3%)
had developmental delay. The gelastic seizure was significantly associated with sessile type HH
rather than pedunculated type HH (85.7% vs. 18.8%, p = 0.001). After GnRH agonist treatment,
discrepancies between bone age and chronological age decreased (3.3 ± 1.3 years to 2.0 ± 1.7 years,
p = 0.002). Additionally, height standard deviation score for bone age was increased, and predicted
adult height increased significantly in females, while males showed an increasing trend. Clinical
symptoms of HH were closely associated with the location of HH, and GnRH agonist treatment was
safe and effective in the management of CPP caused by HH.
Keywords: hypothalamic hamartoma; central precocious puberty; gelastic seizure
1. Introduction
Hypothalamic hamartoma (HH) is a rare, congenital, and benign lesion of the tuber
cinereum. It is mainly composed of normal brain tissue, such as neurons, glial cells, and
fiber bundles [1]. The prevalence of HH varies between 1 in every 50,000 and 1 in every
200,000 persons [2–4]. The majority of HH is located at the base of the hypothalamus and
the floor of the third ventricle [5]. It is usually diagnosed by brain magnetic resonance
imaging (MRI) scans and is seen as non-enhancing, isointense, or hyperintense lesions on
T2-weighted images [6,7].
HH is a complex neuroendocrine disease that usually first presents with one of the
three following main symptoms; central precocious puberty (CPP), gelastic seizure, or
developmental delay [8,9]. HH is one of the most common organic causes of CPP [10].
CPP caused by HH tends to occur significantly earlier in life than idiopathic CPP [11]. The
pathophysiology of hypothalamus–pituitary–gonadal axis activation is not completely
understood, but CPP in HH patients is well managed by treatment with a gonadotropin-
releasing hormone (GnRH) agonist [12,13]. Gelastic seizure, also known as laughing
seizure, is a distinct feature of HH [14]. Other various seizure types including generalized
or focal seizures are reported in HH patients [15]. As antiepileptic drugs are frequently
unsuccessful in seizures associated with HH, surgical intervention is often considered
in intractable epilepsy [4,16]. Additionally, behavioral and cognitive disorders are often
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accompanied in HH patients with seizure events, resulting in developmental delay and
diverse psychological problems [2,17].
Previously published research has reported case studies with HH, but most of these
studies focused mainly on seizure control, neuroimaging, and surgical management. Pre-
vious studies focusing on CPP in HH are sparse, while studies concerning longitudinal
follow-up data of CPP patients are especially rare. In this study, clinical characteristics, labo-
ratory results, and image findings of HH are explored. Further, we investigated CPP in HH
patients and compared clinical features between before and after GnRH agonist treatment.
2. Materials and Methods
2.1. Patients
A total of 30 patients under 18 years of age with HH who visited Severance Children’s
Hospital between January 2005 and May 2020 were retrospectively reviewed. The diagnosis
of HH was based on MRI scans. This study was approved by the Institutional Review
Board of Severance Hospital, Yonsei University College of Medicine in Seoul, Korea (no.
4-2020-0241). The requirement to obtain informed consent was waived.
2.2. Study Design
Patient data, including sex, age at symptom onset, age at diagnosis, symptom at
first visit, additional symptoms during follow-up, and type of received treatment, were
reviewed. Additionally, brain MRI findings such as size and type of HH were gathered.
CPP was diagnosed when the peak LH level was 5 ≥ IU/L on GnRH stimulation test before
8 years of age in girls and before 9 years of age in boys. In CPP patients, further clinical
and biochemical data were collected, including age at diagnosis of CPP, height, weight,
body mass index (BMI), serum luteinizing hormone (LH), follicle-stimulating hormone
(FSH), prolactin, estradiol, testosterone, peak LH level on GnRH stimulation test, pubertal
development stage, bone age, and duration of GnRH agonist treatment.
Brain MRI scans were acquired using a Philips 3.0T scanner (Philips Achieva 3.0T;
Philips Medical Systems, Best, The Netherlands). Type of HH was determined based on
brain location on MRI, and cases were classified into either pedunculated (parahypothala-
mic) type or sessile (intrahypothalamic) type [6,8,9]. Height standard deviation score (SDS)
for chronological age, height SDS for bone age, weight SDS, and BMI SDS were calculated
using the growth standard of Korean children and adolescents [18]. Serum LH, FSH, and
prolactin levels were measured using sequential 2-step immunoenzymatic assays (Access
Reagent Pack, Beckman Coulter Inc., Brea, CA, USA), with an intra-assay coefficient of
variation (CV) of 3.5–5.4%, inter-assay CV of 4.3–6.4%, and a lower limit of detection of
0.2 IU/L for both gonadotropins. Serum E2 levels were measured using radioimmuno
assays (Coat-A-Count Estradiol, Siemens, Erlangen, Germany), and serum testosterone
levels were measured by chemiluminescent microparticle immunoassays (Architect i2000
analyzer, Abbott Diagnostics, Chicago, IL, USA). Pubertal development was determined
using the Marshall and Tanner staging system [19,20]. Bone age was examined by per-
forming radiography of the left hand and wrist and interpreted using the Greulich and
Pyle (GP) method [21]. Predicted male and female adult height were estimated using the
Bayley–Pinneau (BP) method [22]. All patients with CPP were treated with GnRH agonist
every four weeks, either leuprolide acetate (3.75 mg) or triptorelin acetate (3.75 mg). GnRH
agonist treatment was maintained until bone age reached 12 to 12.5 years in girls and
13 years in boys.
2.3. Statistical Analysis
Statistical analyses were performed using IBM SPSS ver. 25.0 (IBM Corp., Armonk,
NY, USA). Anthropometric data, hormone levels, size of HH, tanner stage, bone age,
and predicted adult height are presented as the mean ± SD. Fisher’s exact test was used
to analyze the association between clinical symptoms and type of HH, and the paired
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t-test was applied to compare data before GnRH agonist treatment and after treatment. A
p-value < 0.05 was considered statistically significant.
3. Results
3.1. Clinical Characteristics of Patients with HH
Among the total 30 HH patients, 14 patients were male (46.7%) and 16 patients
were female (53.3%). Mean age at onset of first symptom was 2.9 ± 2.5 years, and age
at diagnosis of HH was 4.2 ± 2.9 years. Twelve patients (40.0%) came to the hospital
presenting precocious puberty as a first symptom, while nine patients (30.0%) had a
gelastic seizure as the chief complaint for the first visit. Seven patients presented with
other types of seizures, such as generalized tonic-clonic seizure (n = 3), simple partial
seizure (n = 2), focal seizure (n = 1), and infantile spasm (n = 1). During the follow-up,
24 patients (80.0%) were diagnosed with CPP, 15 patients (50.0%) had gelastic seizure,
and 13 patients (43.3%) had developmental delay. Twelve patients (40.0%) had surgical
operation, and two patients (6.7%) underwent gamma-knife surgery. All 24 CPP patients
received GnRH agonist treatment. Two patients were diagnosed with growth hormone
deficiency by growth hormone stimulation test and received growth hormone treatment
(Table 1).
Table 1. Characteristics of patients with hypothalamic hamartoma.
Characteristics Value
Sex
Male/Female 14 (46.7%)/16 (53.3%)
Age at symptom onset (year) 2.9 ± 2.5
Age at diagnosis (year) 4.2 ± 2.9
Symptom at first visit
Precocious puberty 12 (40.0%)
Gelastic seizure 9 (30.0%)
Other seizures 7 (23.3%)
Headache 1 (3.3%)
Developmental delay 1 (3.3%)
Symptoms during follow-up
Precocious puberty 24 (80.0%)
Gelastic seizure 15 (50.0%)
Developmental delay 13 (43.3%)
Treatment
Surgical operation 12 (40.0%)
Gamma-knife surgery 2 (6.7%)
GnRH agonist treatment 24/24 (100%)
Growth hormone treatment 2 (6.7%)
Type of hypothalamic hamartoma
Pedunculated/Sessile 16 (53.3%)/14 (46.7%)
Size of hypothalamic hamartoma (mm) 17.8 ± 9.2
Data are presented as mean ± SD or number of patients (%).
3.2. Association between Clinical Manifestations and Type of HH
Type of HH was classified into pedunculated type or sessile type according to its
location on brain MRI scans. Of the 30 patients, 16 patients (53.3%) had pedunculated-
type HH while 14 patients (46.7%) had sessile type. Mean size of HH was 17.8 ± 9.2 mm
(Table 1). Association between the type of HH and the classic triad of symptoms (precocious
puberty, gelastic seizure, and developmental delay) is summarized in Table 2. Pedunculated
type of HH had a higher prevalence of precocious puberty than sessile type (87.5% vs.
71.4%), but the difference was not significant (p = 0.378). Twelve of fourteen patients
(85.7%) with sessile type HH had gelastic seizure, while only three of sixteen (18.8%)
pedunculated-type patients presented gelastic seizures (p = 0.001). Developmental delay
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showed a preponderance of sessile type over pedunculated type, but the difference was
not statistically significant (64.3% vs. 25.0%, p = 0.063).
Table 2. Association between type of HH and symptom triad.
Sessile Type Pedunculated Type p Value
Precocious puberty 10/14 (71.4%) 14/16 (87.5%) 0.378
Gelastic seizure 12/14 (85.7%) 3/16 (18.8%) 0.001
Developmental delay 9/14 (64.3%) 4/16 (25.0%) 0.063
3.3. Management of Central Precocious Puberty in HH Patients
Among the 24 CPP patients, 11 patients (45.8%) were male, and 13 patients (54.2%) were
female. Mean age at diagnosis of CPP was 5.7 ± 3.1 years. Basal LH level was 2.48 ± 1.31 IU/L,
estradiol was 25.74 ± 23.00 pg/mL, and testosterone was 227.26 ± 291.82 ng/dL. LH peak of
GnRH stimulation test was 27.92 ± 18.94 IU/L. Breast tanner stage on diagnosis of CPP
was 2.8 ± 0.6 and testis size was 12.1 ± 7.1 cc (Table 3).
Table 3. Characteristics of hypothalamic hamartoma patients with central precocious puberty
(n = 24).
Characteristics Value
Male/female 11 (45.8%)/13 (54.2%)
Age at diagnosis of CPP (year) 5.7 ± 3.1
Basal hormone levels at diagnosis
LH (IU/L) 2.48 ± 1.31
FSH (IU/L) 4.18 ± 2.73
Estradiol (pg/mL) (n = 13) 25.74 ± 23.00
Testosterone (ng/dL) (n = 11) 227.26 ± 291.82
Prolactin (ng/mL) 12.95 ± 7.50
LH peak of GnRH stimulation test (IU/L) 27.92 ± 18.94
Breast tanner stage on diagnosis of CPP (n = 13) 2.8 ± 0.6
Testis size on diagnosis of CPP (cc) (n = 11) 12.1 ± 7.1
Duration of GnRH agonist treatment (year) (n = 15) 3.1 ± 2.2
CPP, central precocious puberty; LH, luteinizing hormone; FSH, follicle-stimulating hormone; GnRH,
gonadotropin-releasing hormone. Data are presented as mean ± SD or number of patients (%).
Of the 24 CPP patients, 9 patients were referred to other hospitals, and the remaining
15 patients were continuously followed up in our clinic. Patients underwent GnRH agonist
treatment for 3.1 ± 2.2 years on average (Table 3). Clinical findings of the 15 patients before
and after GnRH agonist treatment are presented in Table 4. Height SDS for chronological
age decreased after GnRH agonist treatment (1.38 ± 1.76 to 0.72 ± 1.38, p = 0.010), while
height SDS for bone age significantly increased (−2.65 ± 1.76 to −1.43 ± 1.15, p = 0.003).
Weight SDS and BMI SDS showed no significant change. Bone age was 3.3 ± 1.3 years
advanced compared to chronological age at diagnosis, which significantly decreased to
2.0 ± 1.7 years after GnRH agonist treatment (p = 0.002). Predicted adult height signif-
icantly increased in females (149.0 ± 8.8 cm to 157.3 ± 9.7 cm, p = 0.006), while males
showed an increasing trend (171.0 ± 12.4 cm to 175.2 ± 8.3 cm, p = 0.066).
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Table 4. Comparison between before and after GnRH agonist treatment (n = 15).
Before GnRH Treatment After GnRH Treatment p Value
Height (cm) 123.7 ± 19.4 141.0 ± 15.0 <0.001
Height SDS for chronological age 1.38 ± 1.76 0.72 ± 1.38 0.010
Height SDS for bone age −2.65 ± 1.76 −1.43 ± 1.15 0.003
Weight (kg) 30.9 ± 12.4 44.8 ± 12.6 <0.001
Weight SDS 1.53 ± 1.17 1.41 ± 0.88 0.450
BMI 19.30 ± 2.88 22.29 ± 3.37 0.001
BMI SDS 1.23 ± 1.26 1.58 ± 0.94 0.214
Bone age (year) 9.9 ± 2.3 11.7 ± 1.9 <0.001
Chronological age (year) 6.6 ± 3.0 9.7 ± 2.7 <0.001
BA–CA (year) 3.3 ± 1.3 2.0 ± 1.7 0.002
Male predicted adult height (cm) (n = 6) 171.0 ± 12.4 175.2 ± 8.3 0.066
Female predicted adult height (cm) (n = 7) 149.0 ± 8.8 157.3 ± 9.7 0.006
GnRH, gonadotropin-releasing hormone; SDS, standard deviation score; BMI, body mass index; BA, bone age; CA, chronological age. Data
are presented as mean ± SD.
4. Discussion
HH is a rare congenital disease only diagnosed by brain imaging, which makes it
difficult to investigate its epidemiology such as prevalence, sex distribution, and clinical
features. Some previous studies reported that HH is slightly more common in males, but
the differences were not remarkable. Parvizi et al. reported that 59 of 100 (59.0%) HH
patients were male [15], and Nguyen et al. found that 136 of 256 patients (53.1%) were
male [4]. However, our study population showed nearly equal distribution among both
sexes (14 male patients and 16 female patients). Additionally, HH is usually confirmed by
brain MRI scans during the further evaluation of pubertal development or seizure events,
which generally onsets in the early years in life. Corbet Burcher et al. reported that the
mean age at symptom onset was 1.5 years based on a systematic review of 264 HH patients,
and the mean age at diagnosis of HH was 2.4 years in their cohort with 46 HH children [17].
Our results showed a mean age of 2.9 years at symptom onset, and age at diagnosis of HH
was 4.2 years, which is slightly older than previous studies [4,23,24].
HH has often been characterized by its distinct clinical symptoms. The majority of
HH patients first visit hospitals complaining of early pubertal development or seizures.
In our study, CPP was the most common first symptom, found in 12 patients, followed
by gelastic seizure in 9 patients. However, considering that seven patients experienced
other types of seizures at first visit, over half of the patients (16 of 30 patients, 53.3%) first
presented with seizures. The prevalence of CPP in HH patients from our study is 80.0%
(24 of 30 patients), which is relatively higher than in previous reports (28 of 67 patients,
41.7% [7], and 46 of 100 patients, 46.0% [15]). However, some other researches showed a
higher prevalence of CPP in HH patients (174 of 277 patients, 62.8% [4], 115 of 214 patients,
53.7% [25]). Unlike other previous cross-sectional studies, we continuously followed up
HH patients without CPP at first visit, and 12 patients had newly developed CPP during
the observation. This longitudinal design of this study could have influenced differences
in the prevalence of CPP in our HH patients.
HH is classified into either pedunculated type or sessile type based on its location
in brain MRI scans. The association between the type of HH and clinical symptoms was
investigated in many previous studies, showing a close relationship between pedunculated
type HH and CPP. Further, a high correlation has been reported between the sessile type
HH and gelastic seizure with accompanying developmental delay [4,8,24–26]. Our data
showed similar results in terms of gelastic seizure, which was highly associated with sessile
type HH. Additionally, CPP was more commonly diagnosed in the pedunculated type,
but the results were not statistically significant. The developmental delay also showed a
tendency toward sessile type HH.
Seizure in HH patients is often first treated with antiepileptic drugs, but the results
are usually unsuccessful [15,27,28]. Surgical management is considered in patients with
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medically intractable seizure, which can make epileptic patients seizure-free and improve
cognition and behavior problems. Various surgical techniques have been devised, such
as microsurgical resection, endoscopic disconnection, stereotactic radiosurgery, radiofre-
quency ablation, and vagal nerve stimulation [29–31]. In our study, 19 of 30 patients had
seizure history, while gelastic seizure was most commonly seen in 15 patients. Among the
19 seizure patients, 12 patients underwent surgical resection, and 2 patients underwent
gamma-knife surgery. The mean timing of surgery was 5.7 years after initiation of phar-
macological treatment. Among the 14 surgery patients, 8 patients were seizure-free after
surgery and 6 patients had improvement of seizure activity. However, we did not observe
any changes in seizure patterns in patients with GnRH agonist treatment. None of the
11 HH patients who had no seizure events received surgical intervention.
The mechanism of HH triggering the onset of puberty is not clearly understood,
but there are a few proposed hypotheses. Previous studies suggested that HH controls
GnRH secretion in several ways, such as producing ectopic GnRH within the HH itself or
controlling nearby neurons synaptically connected to GnRH neurons [13,31,32]. Research
by Chan et al. emphasized that the anatomic features of HH are more responsible for
arousing pubertal development [33]. In any case, whatever the exact mechanism of the
onset of puberty in HH patients may be, CPP caused by HH is well controlled by GnRH
agonist treatment [12,23,34,35]. In our study, 15 CPP patients continuously received GnRH
agonist treatment for an average of 3.1 years and had no suspected unexpected serious
adverse reactions. All girls had their menarche at a mean duration of 17 months after
discontinuation of GnRH agonist treatment. All 15 patients had follow-up brain MRI scans
after starting GnRH agonist treatment, and there were no interval changes in HH size. We
used three parameters to evaluate the efficacy of GnRH agonist treatment; the discrepancy
between bone age and chronological age, height SDS for bone age, and predicted adult
height by the BP method. After GnRH agonist treatment, bone age advancement was
ameliorated by 1.3 years, and height SDS for bone age significantly increased. Additionally,
predicted adult height by the BP method increased significantly in females, while males
showed an increasing, but not statistically significant, trend.
There are some limitations to this study. Among the 24 CPP patients, 9 HH patients
with CPP were referred to other hospitals, and the remaining 15 patients received GnRH
agonist treatment continuously in our outpatient clinic. As GnRH agonist treatment is
mainly based on monthly injection, patients prefer getting injections at hospitals near their
residential area, resulting in a high proportion of follow-up loss. Additionally, we used the
BP method to predict final adult height in HH patients with CPP. While the BP method
is one of the most long-standing and widely used methods to predict adult height, it has
some limitations. The BP method was established in the 1950s based on American children,
which might be inadequate to apply directly to Korean children in the 21st century. Further,
predicted adult height calculation by the BP method is not available in children with
skeletal age (bone age) younger than six, and it is impossible to predict adult height in
children of extremely high stature by the BP method. Lastly, 4 of 15 CPP patients are still
under treatment of GnRH agonist, and 6 patients had surgical operation or gamma-knife
surgery, which could have influenced our analysis. Further studies with a larger sample
size and a longer follow-up period are required to elucidate more detailed results.
5. Conclusions
In summary, we investigated clinical characteristics, laboratory results, and brain MRI
findings in 30 HH patients. Gelastic seizure was closely associated with sessile type HH,
while CPP showed a tendency toward pedunculated type HH. In addition, based on 15 HH
patients with CPP, we can reconfirm the safety and efficacy of GnRH agonist treatment in
HH patients with CPP.
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